הודעה על החמרה (מידע בטיחות) בעלון לרופא

(מעודכן 05/2013)

January 20, 2015 _	תאריד
--------------------	-------

שם תכשיר באנגלית ומספר הרישום
STINE Solution for Injection

VINCRISTINE Solution for Injection 115 51 22790 05

Salomon, Levin & Elstein Ltd. POBox 3696, Petach-Tikva 49133 שם בעל הרישום

טופס זה מיועד לפרוט החמרות בלבד!

ההחמרות המבוקשות		
טקסט חדש	טקסט נוכחי	פרק בעלון
		Indication
in patients who are hypersensitive to active substance or to any excipient listed in section 6.1 vincristine sulphate or to one of the excipients:	in patients who are hypersensitive to vincristine sulphate or to one of the excipients;	contraindications
		Posology, dosage & administration
'VINCRISTINE FOR INTRAVENOUS USE ONLY, FATAL IF GIVEN BY OTHER ROUTES' Intrathecal administration of vincristine results in fatal neurotoxicity.	VINCRISTINE FOR INTRAVENOUS USE ONLY, FATAL IF GIVEN BY OTHER ROUTES' Intrathecal administration of vincristine results in fatal neurotoxicity.	Special Warnings and Special Precautions for Use
		Interaction with Other Medicaments and Other Forms of
		Interaction
		pregnancy and Fertility,
Nervous system disorders		Lactation Adverse events
Not known: Leukoencephalopathy		Adverse events
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form (http://forms.gov.il/globaldata/getsequence/ge tsequence.aspx?formType=AdversEffectMedice@moh.gov.il).		